Anticancer efficacy and the mechanism of action of α-
santalol, a
terpenoid isolated from
sandalwood oil, were investigated in human
breast cancer cells by using p53 wild-type MCF-7 cells as a model for
estrogen receptor (ER)-positive and p53 mutated MDA-MB-231 cells as a model for ER-negative
breast cancer. α-
Santalol inhibited cell viability and proliferation in a concentration and time-dependent manner in both cells regardless of their ER and/or p53 status. However, α-
santalol produced relatively less toxic effect on normal breast epithelial cell line, MCF-10A. It induced G2/M cell cycle arrest and apoptosis in both MCF-7 and MDA-MB-231 cells. Cell cycle arrest induced by α-
santalol was associated with changes in the
protein levels of BRCA1, Chk1, G2/M regulatory
cyclins,
Cyclin dependent kinases (CDKs), Cell division cycle 25B (Cdc25B), Cdc25C and Ser-216 phosphorylation of Cdc25C. An up-regulated expression of CDK inhibitor p21 along with suppressed expression of mutated p53 was observed in MDA-MB-231 cells treated with α-
santalol. On the contrary, α-
santalol did not increase the expression of wild-type p53 and p21 in MCF-7 cells. In addition, α-
santalol induced extrinsic and intrinsic pathways of apoptosis in both cells with activation of
caspase-8 and
caspase-9. It led to the activation of the executioner
caspase-6 and
caspase-7 in α-
santalol-treated MCF-7 cells and
caspase-3 and
caspase-6 in MDA-MB-231 cells along with strong cleavage of
poly(ADP-ribose) polymerase (PARP) in both cells. Taken together, this study for the first time identified strong anti-neoplastic effects of α-
santalol against both ER-positive and ER-negative
breast cancer cells.